Previous 10 | Next 10 |
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was...
Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero. While this is still...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Sne...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...
The Phase III clinical trial, Flamingo-01, is now registered on clinicaltrials.gov with identifier NCT05232916 (view here ), where more details about the trial design and a preliminary listing of the initial clinical sites can be found Company management will be attending ...
Greenwich LifeSciences (GLSI +24.4%) is enjoying substantial gains Thursday, continuing a winning streak that began on Tuesday. From the close of trading Monday through Wednesday's close, shares rose ~11%. Year to date through Wednesday's close, shares are down 16%. The recent ...
Gainers: Dermata (NASDAQ:DRMA) +25%. IronNet (NYSE:IRNT) +25%. China Online Education (NYSE:COE) +25%. Greenwich LifeSciences (NASDAQ:GLSI) +25%. CleanSpark (NASDAQ:CLSK) +24%. Ebang International Holdings (NASDAQ:EBON) +22%. Lufax Holding (NYSE:LU) +22%. Vaccinex (NASDAQ:VCNX) +21%. The Vale...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that Sne...
Greenwich LifeSciences (NASDAQ:GLSI) provides an update on the Phase III clinical trial, FLAMINGO-01. The combination of GP2 + GM-CSF will be called GLSI-100. The Phase III trial is comprised of 2 placebo-controlled arms for approx. 500 HLA-A*02 patients and 1 open label arm of up to 100 pati...
- The GP2 Phase III clinical trial poster was presented in person at the 2021 annual San Antonio Breast Cancer Symposium (SABCS). The Company was a SABCS sponsor and held a clinical trial planning meeting with investigators at the conference. The poster can be seen here . - Crit...
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
2024-04-02 01:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their conf...